.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,211,600

« Back to Dashboard
Patent 7,211,600 protects SUTENT and is included in one NDA. There has been one Paragraph IV challenge on Sutent. There is one tentative approval for the compound protected by this patent. Additional details are available via the generic ingredient links below.

This patent has thirteen patent family members in thirteen countries.

Summary for Patent: 7,211,600

Title:Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
Abstract:The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity c-kit kinase.
Inventor(s): Lipson; Ken (San Mateo, CA), McMahon; Gerald (Kenwood, CA)
Assignee: Sugen Inc. (South San Francisco, CA)
Application Number:11/205,474
Patent Claim Types:
see list of patent claims
Use; Device;
Patent Metrics:
Source: PatentQuant.com
Field: Basic materials chemistry
Back Citations: 23rd percentile
Forward Citations: 3rd percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Cppi Cv
SUTENT
sunitinib malate
CAPSULE;ORAL021938-001Jan 26, 2006RXNo7,211,600► subscribe TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB
Cppi Cv
SUTENT
sunitinib malate
CAPSULE;ORAL021938-002Jan 26, 2006RXNo7,211,600► subscribe TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB
Cppi Cv
SUTENT
sunitinib malate
CAPSULE;ORAL021938-004Mar 31, 2009RXNo7,211,600► subscribe TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,211,600

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria331514► subscribe
Australia3436301► subscribe
Australia784266► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc